Tricitrasol

The

Refer to the manufacturer's Operator's Manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure.

The apheresis system will control the amount of the citrate/6% solution of HES that is added to the whole blood and the method of administration of the solution. Refer to the Operator's Manual of the apheresis medical device.

Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant ^{1. 9 11}. The recipient of the citrated blood product should be monitored for the signs and symptoms of citrate toxicity ^{1. 9 11}. The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions that are characterized by hypotension and possible cardiac arrhythmia ^{1. 9 11}. Citrate toxicity may occur more frequently in patients that are hypothermic ¹⁰, have impaired liver or renal function ¹⁰, or have low calcium levels because of an underlying disease ⁹.

There are no adverse reactions for the addition of the product to the rouleaux agent.

Each 30 mL of

pH adjusted with Citric Acid

pH: 6.3 – 6.6

Single patient use only, on a single occasion.